10.01.20
An in-vivo study published in the research journal Osteoarthritis and Cartilage found that a native type II collagen ingredient, Bioiberica’s b-2cool, was able to improve joint health in combination with a number of key ingredients, which included chondroitin sulphate, glucosamine hydrochloride, and hyaluronic acid (Bioiberica’s Mobilee).
“This study is a key development in Bioiberica’s joint health research,” Jaume Reguant, director of Healthcare at Bioiberica, said. “It complements previous research by providing additional validation for the benefits of using native type II collagen in innovative mobility solutions and allows Bioiberica to further position b-2cool as a trusted ingredient for effective joint health formulations.”
“As younger, more health-conscious consumers take more of an interest in their mobility, the joint health market must evolve to appeal beyond the senior population,” he continued. “These audiences are interested in comprehensive solutions that target overall mobility and help them live life to the fullest as they age. These new results show the effectiveness of combining Bioiberica’s ingredients for joint health and opens up new opportunities for manufacturers looking to expand their portfolio and explore more holistic mobility offerings for consumers.”
The study, conducted in a rabbit model of osteoarthritis, an age-related degradation of tissues connected to bone which is considered the most common arthritis form, set out to evaluate the effects of b-2cool collagen in combination with a host of other ingredients.
During the study the animals were divided into either a control group, one treated with chondroitin sulphate, glucosamine hydrochloride and Mobilee (a rooster comb extract high in hyaluronic acid), or the third group, which received the same combination with the addition of b-2cool.
The b-2cool group showed the lowest degree of cartilage degeneration, signs of less advanced osteoarthritis, healthier cartilage and joints, and significantly better synovial membrane values on histology, the authors of the study reported. Combined with other research on native type II collagen, this research supports that a 40 mg daily dose of b-2cool helps to maintain healthy joints, through an effect exerted by a mechanism of action called oral tolerance.
b-2cool is supported by four preclinical studies and clinical trials which have shown statistically significant results in a number of metrics indicating healthy joints and quality of life, as both a standalone ingredient and in combined solutions.
“This study is a key development in Bioiberica’s joint health research,” Jaume Reguant, director of Healthcare at Bioiberica, said. “It complements previous research by providing additional validation for the benefits of using native type II collagen in innovative mobility solutions and allows Bioiberica to further position b-2cool as a trusted ingredient for effective joint health formulations.”
“As younger, more health-conscious consumers take more of an interest in their mobility, the joint health market must evolve to appeal beyond the senior population,” he continued. “These audiences are interested in comprehensive solutions that target overall mobility and help them live life to the fullest as they age. These new results show the effectiveness of combining Bioiberica’s ingredients for joint health and opens up new opportunities for manufacturers looking to expand their portfolio and explore more holistic mobility offerings for consumers.”
The study, conducted in a rabbit model of osteoarthritis, an age-related degradation of tissues connected to bone which is considered the most common arthritis form, set out to evaluate the effects of b-2cool collagen in combination with a host of other ingredients.
During the study the animals were divided into either a control group, one treated with chondroitin sulphate, glucosamine hydrochloride and Mobilee (a rooster comb extract high in hyaluronic acid), or the third group, which received the same combination with the addition of b-2cool.
The b-2cool group showed the lowest degree of cartilage degeneration, signs of less advanced osteoarthritis, healthier cartilage and joints, and significantly better synovial membrane values on histology, the authors of the study reported. Combined with other research on native type II collagen, this research supports that a 40 mg daily dose of b-2cool helps to maintain healthy joints, through an effect exerted by a mechanism of action called oral tolerance.
b-2cool is supported by four preclinical studies and clinical trials which have shown statistically significant results in a number of metrics indicating healthy joints and quality of life, as both a standalone ingredient and in combined solutions.
